Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Optic, Atrophy, Hereditary, Leber

Interventions

BIOLOGICAL: GS010
DEVICE: Sham Intravitreal Injection

Sponsor

GenSight Biologics